NCT04132570View on ClinicalTrials.gov

A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution

PHASE4CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions
Rhinitis
Interventions
DRUG

Budesonide

Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.

OTHER

Placebo

Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.

Trial Locations (6)

100730

Beijing Tongren Hospital, Cmu, Beijing

250117

Shandong provincial hospital, Jinan

261041

The No.2 People'S Hospital Og Weifang, Weifang

071051

The No.2 Hospital of Baoding, Baoding

061000

Cangzhou Center Hospital, Cangzhou

050000

The Second Hospital to Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division

INDUSTRY

NCT04132570 - A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution | Biotech Hunter | Biotech Hunter